Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

For adult and pediatric patients with hemophilia A

Help Him REACH HIGHER With Long-lasting Protection

AFSTYLA is the first and only recombinant Factor VIII that delivers proven, long-lasting bleed protection with a novel single-chain design

Explore the benefits of AFSTYLA

Twice-weekly dosing available

Flexible dosing—2x or 3x weekly to meet your patients' needs

View AFSTYLA dosing recommendations

ZERO bleeds (median AsBR*)

In all studied populations regardless of dosing regimen

Explore AFSTYLA efficacy

Comparable to natural Factor VIII

Amino acid sequence is identical to endogenous Factor VIII once activated

Learn about the science of AFSTYLA

*Annualized spontaneous bleeding rate in clinical trials (IQR=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).


Zero inhibitors among previously
treated patients in clinical trials;
low incidence of adverse reactions (n=258)

See safety profile

Getting your patients started is simple

  • Start patient on AFSTYLA with a free 30-day trial
  • Fill out an AFSTYLA Patient Referral form to start the trial, enroll your patient in the AFSTYLA Support program, and begin a benefits investigation
  • Fax the completed form to My SourceSM at 1-844-727-2757

See what additional resources are available for you and your patients


to get detailed information
about services available to
your patients

Monday-Friday, 8 am to 8 pm ET

Find out first!

Sign up and stay up to date. Get breaking news and information about AFSTYLA.

Email address
You are now leaving the current website.

Do you want to continue?

No Yes